Late-breaking abstract: The effects of roxithromycin as anti-inflammatoy agent on clinical outcomes in patient with bronchiectasis: A double blinded randomized controlled study

S. Juthong, S. Eiamsa-ard (HatYai, Thailand)

Source: Annual Congress 2011 - Late-Breaking Abstracts Session: New treatments and targets for airway disease
Session: Late-Breaking Abstracts Session: New treatments and targets for airway disease
Session type: Oral Presentation
Number: 4496
Disease area: Airway diseases

Congress or journal article abstractE-posterSlide presentation

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
S. Juthong, S. Eiamsa-ard (HatYai, Thailand). Late-breaking abstract: The effects of roxithromycin as anti-inflammatoy agent on clinical outcomes in patient with bronchiectasis: A double blinded randomized controlled study. Eur Respir J 2011; 38: Suppl. 55, 4496

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Clinical effect on asthma control using a novel digital self-management solution: a physician blinded randomized controlled crossover trial
Source: International Congress 2019 – Medical education to improve practice
Year: 2019




Placebo effects in pharmaceutical clinical trials in bronchiectasis: an EMBARC study
Source: Virtual Congress 2020 – New investigations of bronchiectasis and non-tuberculous mycobacteria
Year: 2020


Late Breaking Abstract - A randomised, double-blind, placebo controlled, clinical trial evaluating imatinib in patients with severe COVID-19
Source: Virtual Congress 2021 – Late breaking basic and translational science of SARS-Cov2 and COVID-19
Year: 2021



The role of phonophoresis in patients with COPD: a randomized clinical trial
Source: Virtual Congress 2020 – Clinical and basic pharmacology for COPD
Year: 2020


Azithromycin for treatment of hospitalised COVID-19 patients: a randomised, multicentre, open-label clinical trial (DAWn-AZITHRO)
Source: ERJ Open Res, 8 (1) 00610-2021; 10.1183/23120541.00610-2021
Year: 2022



Clinical effect on uncontrolled asthma using a novel digital automated self-management solution: a physician-blinded randomised controlled crossover trial
Source: Eur Respir J, 54 (5) 1900983; 10.1183/13993003.00983-2019
Year: 2019



Effect of salmetrol-fluticason combination and tiotropium on clinical and physiological improvement of bronchial anthracofibrosis, a double blind randomized, cross over, placebo controlled, clinical trial.
Source: International Congress 2017 – Towards better treatments for lung disease: experimental pharmacology
Year: 2017


RCT Abstract - The efficacy and safety of colistimethate sodium delivered via the I-neb in bronchiectasis: the PROMIS-I randomized controlled trial
Source: Virtual Congress 2021 – ALERT: bronchiectasis and COVID
Year: 2021



Cardiac impact of inhaled therapy in the largest randomised placebo-controlled trial in COPD history: have we reached the SUMMIT?
Source: ERJ Open Res 2016: 00055-2016
Year: 2016



Clinical effectiveness of MDI-HFA-Modulite budesonide in the treatment of asthma – meta-analysis of randomised controlled trials
Source: Eur Respir J 2006; 28: Suppl. 50, 315s
Year: 2006

Acetylcysteine in treatment of subacute sinusitis, a double blind placebo controlled clinical trial study
Source: Annual Congress 2010 - Treatment and risk factors in lower respiratory tract infections
Year: 2010


Azithromycin and hydroxychloroquine in hospitalised patients with confirmed COVID-19: a randomised double-blinded placebo-controlled trial
Source: Eur Respir J, 59 (1) 2100752; 10.1183/13993003.00752-2021
Year: 2022



Pivot trial A multicentre randomised controlled equivalence trial comparing oral amoxycillin and intravenous penicillin for community acquired pneumonia in children
Source: Eur Respir J 2004; 24: Suppl. 48, 714s
Year: 2004

Multicenter, randomized, double-blind, placebo-controlled study (ORBIT 1) to evaluate the efficacy, safety, and tolerability of once daily ciprofloxacin for inhalation in the management of pseudomonas aeruginosa infections in patients with non-cystic fibrosis bronchiectasis
Source: Annual Congress 2011 - Advances in antibiotic therapy of non-cystic fibrosis bronchiectasis
Year: 2011

Long term azithromycin treatment: A randomised placebo-controlled trial in non-CF bronchiectasis; results from the BAT trial
Source: Annual Congress 2011 - Advances in antibiotic therapy of non-cystic fibrosis bronchiectasis
Year: 2011


Run-in bias in randomised trials: the case of COPD medications
Source: Eur Respir J, 49 (6) 1700361; 10.1183/13993003.00361-2017
Year: 2017



Azithromycin for the treatment of cough in idiopathic pulmonary fibrosis: A randomized controlled cross-over pilot trial.
Source: Virtual Congress 2020 – Chronic cough: only symptom or disease?
Year: 2020




No gender-related bias in COPD diagnosis and treatment in Sweden: a randomised, controlled, case-based trial
Source: ERJ Open Res, 6 (4) 00342-2020; 10.1183/23120541.00342-2020
Year: 2020



RCT Abstract - Using a smartphone application in COPD patients to increase physical activity following pulmonary rehabilitation. Results of the AMOPUR Study, a multicenter, randomized, controlled study
Source: Virtual Congress 2021 – A multidisciplinary approach to the management of chronic respiratory diseases
Year: 2021